| Literature DB >> 27120117 |
Ji Hyeon Kim1,2, Eunkyoung Kim1, Won Hoon Choi1,2, Jeeyoung Lee1,2, Jung Hoon Lee1, Hyojin Lee2,3, Dong-Eun Kim4, Young Ho Suh2,3, Min Jae Lee1,2,5.
Abstract
Tau is a cytosolic protein that functions in the assembly and stabilization of axonal microtubule networks. Its oligomerization may be the rate-limiting step of insoluble aggregate formation, which is a neuropathological hallmark of Alzheimer's disease (AD) and a number of other tauopathies. Recent evidence indicates that soluble tau oligomers are the toxic species for tau-mediated pathology during AD progression. Herein, we describe novel RNA aptamers that target human tau and were identified through an in vitro selection process. These aptamers significantly inhibited the oligomerization propensity of tau both in vitro and in cultured cell models of tauopathy without affecting the half-life of tau. Tauopathy model cells treated with the aptamers were less sensitized to proteotoxic stress induced by tau overexpression. Moreover, the tau aptamers significantly alleviated synthetic tau oligomer-mediated neurotoxicity and dendritic spine loss in primary hippocampal neurons. Thus, our study demonstrates that delaying tau assembly with RNA aptamers is an effective strategy for protecting cells under various neurodegenerative stresses originating from pathogenic tau oligomerization.Entities:
Keywords: Alzheimer’s disease; SELEX; aggregation; aptamer; inhibition; neurotoxicity; oligomerization; tau; tauopathy
Mesh:
Substances:
Year: 2016 PMID: 27120117 DOI: 10.1021/acs.molpharmaceut.6b00165
Source DB: PubMed Journal: Mol Pharm ISSN: 1543-8384 Impact factor: 4.939